Paul Herzich
Chief Tech/Sci/R&D Officer at SOLID BIOSCIENCES INC.
Net worth: 80 213 $ as of 2024-03-30
Profile
Paul Herzich is currently the Chief Technology Officer at Solid Biosciences, Inc. Prior to this, he held positions as Director-CGMP & Senior Manager at Bamboo Therapeutics, Inc., Senior Director-Manufacturing at LogicBio Therapeutics, Inc., Vice President-CMC at BridgeBio Pharma, Inc., and Chief Technology Officer at Aavantibio, Inc. He also served as Head-TD Manufacturing at Csl Seqirus from 2007 to 2015.
Dr. Herzich received an undergraduate degree from Rutgers State University of New Jersey and an MBA from Poole College of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
SOLID BIOSCIENCES INC.
0.02% | 2024-02-12 | 6,022 ( 0.02% ) | 80 213 $ | 2024-03-30 |
Paul Herzich active positions
| Companies | Position | Start |
|---|---|---|
| SOLID BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 2022-11-30 |
Former positions of Paul Herzich
| Companies | Position | End |
|---|---|---|
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Chief Tech/Sci/R&D Officer | 2022-11-30 |
| BRIDGEBIO PHARMA, INC. | Corporate Officer/Principal | 2021-03-31 |
| LOGICBIO THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-06-30 |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Corporate Officer/Principal | 2017-12-31 |
| Csl Seqirus | Corporate Officer/Principal | 2015-06-30 |
Training of Paul Herzich
| Rutgers State University of New Jersey | Undergraduate Degree |
| Poole College of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SOLID BIOSCIENCES INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Bamboo Therapeutics, Inc.
Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL. | Health Technology |
| Csl Seqirus |
- Stock Market
- Insiders
- Paul Herzich
